Search Results - "Zhugrova, E S"

Long-term efficacy and safety of netakimab in patients with active ankylosing spondylitis: results of three years of use in the international multicentre, randomized, double-blind, phase III clinical trial BCD-085-5/ASTERA by Mazurov, V. I., Erdes, Sh. F., Gaydukova, I. Z., Dubinina, T. V., Pristrom, A. M., Kunder, E. V., Soroka, N. F., Kastanayan, A. A., Povarova, T. V., Zhugrova, E. S., Plaksina, T. V., Shesternya, P. A., Kropotina, T. V., Antipova, O. V., Smolyarchuk, E. A., Tsyupa, O. A., Abdulganieva, D. I., Lapshina, S. A., Krechikova, D. G., Gordeev, I. G., Nesmeyanova, O. B., Ilivanova, E. P., Strelkova, A. V., Tyrenko, V. V., Mikhailova, E. A., Eremeeva, A. V.

“…The article presents the results of the three-year use of netakimab (NTK) in patients with ankylosing spondylitis (AS) as part of the phase III…”
Get full text

Long-term effects of netakimab on health-related quality of life, back pain and work productivity in patients with ankylosing spondylitis: results of the international, multicentre, randomized double-blind phase III clinical trial BCD-085-5/ASTERA by Dubinina, T. V., Demina, A. B., Agafonova, E. M., Erdes, Sh. F., Mazurov, V. I., Gaydukova, I. Z., Pristrom, A. M., Kunder, E. V., Soroka, N. F., Kastanayan, A. A., Povarova, T. V., Zhugrova, E. S., Plaksina, T. V., Shesternya, P. A., Kropotina, T. V., Antipova, O. V., Smolyarchuk, E. A., Tsyupa, O. A., Abdulganieva, D. I., Lapshina, S. A., Krechikova, D. G., Gordeev, I. G., Nesmeyanova, O. B., Tyrenko, V. V., Ilivanova, E. P., Strelkova, A. V.

“…The article contains the data obtained during the 156-week follow-up of patients with ankylosing spondylitis (AS) in the ASTERA phase III study. Objective : to…”
Get full text

Long-term efficacy and safety of netakimab in the treatment of ankylosing spondylitis: results of Phase III international, multicenter, randomized double-blind clinical trial BCD-085-5/ASTERA by Mazurov, V. I., Erdes, Sh. F., Gaydukova, I. Z., Dubinina, T. V., Pristrom, A. M., Kunder, E. V., Soroka, N. F., Kastanayan, A. A., Povarova, T. V., Zhugrova, E. S., Plaksina, T. V., Shesternya, P. A., Kropotina, T. V., Antipova, O. V., Smolyarchuk, E. A., Tsyupa, O. A., Abdulganieva, D. I., Lapshina, S. A., Krechikova, D. G., Gordeev, I. G., Nesmeyanova, O. B., Ilivanova, E. P., Strelkova, A. V., Eremeeva, A. V., Zinkina-Orikhan, A. V.

“…Netakimab (NTK) is a humanized anti-interleukin-17A monoclonal antibody. To date, the drug has been approved to treat ankylosing spondylitis (AS), psoriatic…”
Get full text

Efficacy and safety of netakimab, anti-IL-17A monoclonal antibody, in patients with ankylosing spondylitis. Results of phase III international, multicenter, randomized double-blind clinical trial BCD-085-5/ASTERA by Mazurov, V. I., Gaydukova, I. Z., Erdes, Sh, Dubinina, T. V., Pristrom, A. M., Kunder, E. V., Soroka, N. F., Kastanayan, A. A., Povarova, T. V., Zhugrova, E. S., Plaksina, T. V., Shesternya, P. A., Kropotina, T. V., Antipova, O. V., Smolyarchuk, E. A., Tciupa, O. A., Abdulganieva, D. I., Lapshina, S. A., Krechikova, D. G., Gordeev, I. G., Nesmeyanova, O. B., Tyrenko, V. V., Ilivanova, E. P., Strelkova, A. V., Eremeeva, A. V.

“…Netakimab (NTK) is a humanized monoclonal antibody targeting interleukin-17A. Objective . The main objective of BCD-085-5/ASTERA study was to prove superiority…”
Get full text

DYNAMICS OF CYTOKINE PROFILE IN PATIENTS WITH RHEUMATOID ARTHRITIS AS INFLUENCED BY INFLIXIMAB (REMIKEID) ADMINISTRATION by Zhugrova, E. S., Mazurov, V. I., Lila, A. M., Syssoev, K. A., Lapin, S. V., Totolian, Areg A.

“…Rheumatoid arthritis (RA) is a chronic autoimmune systemic disease with predominantly destructive lesions of peripheral joints, with prevalence of 0.6 to 1.6%…”
Get full text

RISK FACTORS FOR OSTEOPOROSIS IN PATIENTS WITH RHEUMATOID ARTHRITIS (PRELIMINARY RESULTS ACCORDING TO THE MATERIALS OF THE MULTICENTER PROGRAM «OSTEOPOROSIS IN RHEUMATOID ARTHRITIS: DIAGNOSIS, RISK FACTORS, FRACTURES, TREATMENT») by Taskina, E. A., Alekseeva, L. I., Dydykina, I. S., Podvorotova, M. M., Dydykina, P. S., Petrova, E. V., Raskina, T. A., Muradyants, A. A., Zhugrova, E. S., Peshekhonov, D. V., Sizikov, A. E., Sorotskaya, V. N., Bolshakova, T. Yu, Vinogradova, I. B., Dyomin, N. V., Smirnov, A. V., Nasonov, E. L.

“…Osteoporosis (OP) in rheumatoid arthritis (RA) is 2–3 times more common than in the population; however, the data on the risk factors (RFs) of OP in this…”
Get full text

Experience with abatacept used in the treatment of patients with rheumatoid arthritis by Mazurov, V I, Dolgikh, Sergei Vladimirovich, Zhugrova, E S, Shulman, Yu B, Samigullina, R R

“…The efficiency and safety of therapy with abatacept in combination with methotrexate were studied in patients with rheumatoid arthritis. The performed therapy…”
Get full text

Risk factors for fractures in patients with rheumatoid arthritis (preliminary results of the multicenter program «Osteoporosis in rheumatoid arthritis: Diagnosis, risk factors, fractures, treatment») by Podvorotova, Marina Mikhailovna, Dydykina, I S, Taskina, E A, Raskina, T A, Koroleva, M A, Muradyants, A A, Zhugrova, E S, Sinenko, A A, Peshekhonov, D V, Sizikov, A E, Ilyina, N A, Dydykina, P S, Petrova, E V, Sorotskaya, V N, Bolshakova, T Yu, Kapustina, E A, Vinogradova, I B, Alekseyeva, L I, Smirnov, A V, Nasonov, E L

“…In patients with rheumatoid arthritis (RA), bone fractures occur 1.5-2 times more frequently than in the population. They often lead to reduced quality of…”
Get full text

New treatment possibilities for rheumatoid arthritis: the Russian experience in using certolizumab pegol by Karateev, Dmitry Evgenyevich, Nasonov, E L, Denisov, L N, Stanislav, M L, Panasyuk, E Yu, Andrianova, I A, Mazurov, V I, Zhugrova, E S, Uspensky, Yu P, Belousova, L N, Ilivanova, E P, Matsiyevskaya, G K, Aurtyunov, G P, Lytkina, K A, Saikovsky, R S, Ardashev, V N, Zhilyaev, E V, Korshunov, N I

“…Certolizumab pegol (CZP) is a new drug from the group of tumor necrosis factor a inhibitors. The efficacy and safety CZP in the treatment of rheumatoid…”
Get full text

Primeneniya rituksimaba u bol'nykh revmatoidnym artritom: opyt raboty tsentra antitsitokinovoy terapii by Lila, A M, Mazurov, V I, Zhugrova, E S, Zav'yalkina, E V

Get full text

The Effects of Telmisartan and Its Combinations on Office Blood Pressure: Results of Prospective Observational Study TAINA by Ostroumova, O. D., Kochetkov, A. I., Ageev, F. T., Anikin, G. S., Akhmetzyanova, E. Kh, Bezuglova, E. I., Bekoeva, A. B., Borovkova, N. Yu, Vinogradova, N. G., Gorbunova, E. V., Goryacheva, A. A., Zhugrova, E. S., Kislyak, O. A., Klyashev, S. M., Kuzmin, V. P., Lipchenko, A. A., Matyushin, G. V., Mikhailova, E. A., Nevzorova, V. A., Obrezan, A. G., Petrichko, T. A., Petrova, M. M., Reider, A. N., Repin, A. N., Sadovoy, V. I., Sanina, N. P., Skripchenko, A. E., Stryuk, R. I., Faiyance, I. V., Khaisheva, L. A., Khasanov, N. R., Khokhlov, R. A., Tsareva, E. E., Cherkashina, A. L., Shaposhnik, I. I., Shelestova, I. A., Shepel, R. N., Shikh, E. V., Yakhontov, D. A.

“…Aim . To evaluate the effectiveness and safety of telmisartan, used in monotherapy or in combination with hydrochlorothiazide or amlodipine, in real clinical…”
Get full text